Atlas Trials

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Clinical trial NCT03872388 · TERMINATED

Trial details

NCT number
NCT03872388
Sponsor
M.D. Anderson Cancer Center
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Estrogen Receptor NegativeHER2/Neu NegativeInflammatory Breast CarcinomaProgesterone Receptor NegativePrognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8
Start date
2019-09-23
Primary completion
2023-10-19
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.